These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25765186)

  • 1. [Rational estimation of drug dosage through pharmacometric modeling: The case of a long-acting depot antipsychotic].
    Simon N; Azorin JM
    Encephale; 2015 Apr; 41(2):159-67. PubMed ID: 25765186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
    Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
    J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.
    Hard ML; Wehr AY; Sadler BM; Mills RJ; von Moltke L
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):461-469. PubMed ID: 29943125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
    Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
    CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.
    Hard ML; Wehr AY; Du Y; Weiden PJ; Walling D; von Moltke L
    J Clin Psychopharmacol; 2018 Oct; 38(5):435-441. PubMed ID: 30015676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models.
    Jovanović M; Vučićević K; Miljković B
    Drug Metab Rev; 2020 Feb; 52(1):1-18. PubMed ID: 32008418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia.
    Shang DW; Li LJ; Wang XP; Wen YG; Ren YP; Guo W; Li WB; Li L; Zhou TY; Lu W; Wang CY
    Ther Drug Monit; 2014 Jun; 36(3):378-86. PubMed ID: 24342896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method.
    Rothe PH; Heres S; Leucht S
    Schizophr Res; 2018 Mar; 193():23-28. PubMed ID: 28735640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of aripiprazole in healthy Korean subjects.
    Jeon JY; Chae SW; Kim MG
    Int J Clin Pharmacol Ther; 2016 Apr; 54(4):293-304. PubMed ID: 26902506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.
    Kim E; Howes OD; Kim BH; Jeong JM; Lee JS; Jang IJ; Shin SG; Turkheimer FE; Kapur S; Kwon JS
    J Cereb Blood Flow Metab; 2012 Apr; 32(4):759-68. PubMed ID: 22186667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.
    Pilla Reddy V; Kozielska M; Johnson M; Mafirakureva N; Vermeulen A; Liu J; de Greef R; Rujescu D; Groothuis GM; Danhof M; Proost JH
    J Clin Psychopharmacol; 2013 Dec; 33(6):731-9. PubMed ID: 24113674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.
    Hebbrecht K; Morrens M; Neels H; Roosens L; Sabbe BGC
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):999-1005. PubMed ID: 30141352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.
    Perera V; Bies RR; Mo G; Dolton MJ; Carr VJ; McLachlan AJ; Day RO; Polasek TM; Forrest A
    Br J Clin Pharmacol; 2014 Oct; 78(4):800-14. PubMed ID: 24773369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
    Gopal S; Gassmann-Mayer C; Palumbo J; Samtani MN; Shiwach R; Alphs L
    Curr Med Res Opin; 2010 Feb; 26(2):377-87. PubMed ID: 20001492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaches for dosage individualisation in critically ill patients.
    del Mar Fernández de Gatta M; Martin-Suarez A; Lanao JM
    Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1481-93. PubMed ID: 23898816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.
    Gomeni R; Pineau G; Mentré F
    Anticancer Res; 1994; 14(6A):2321-6. PubMed ID: 7825966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended-Release and Long-Acting Injectable Paliperidone.
    Gomeni R; Bressolle-Gomeni F; Fava M
    J Clin Pharmacol; 2016 Oct; 56(10):1296-306. PubMed ID: 26899406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.